DROXIDOPA by Hikma is unknown. Approved for orthostatic dizziness, lightheadedness, the “feeling and 4 more indications. First approved in 2021.
Drug data last refreshed 18h ago
unknown. Droxidopa is a synthetic amino acid analog that is directly metabolized to norepinephrine by dopa-decarboxylase, which is extensively distributed throughout the body. Droxidopa is believed to exert its pharmacological effects through norepinephrine and not through the parent molecule or…
Worked on DROXIDOPA at Hikma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Safety and Efficacy of Droxidopa for Fatigue in Patients With Parkinsonism
Effects of Droxidopa When Measuring Gait Speed, Kyphosis, and Functional Reach in Parkinson's Disease
Sustained Effect of Droxidopa in Symptomatic Neurogenic Orthostatic Hypotension
Phase 3 Study to Evaluate the Efficacy and Safety of Droxidopa on Orthostatic Hypotension Treatment in Hemodialysis Patients